Current status of chemotherapy for the treatment of advanced biliary tract cancer

Korean Journal of Internal Medicine

Volumn 28, Issue 5, 2013, Pages 515-524

  Sasaki, Takashi ^a   Isayama, Hiroyuki ^a   Nakai, Yousuke ^a   Koike, Kazuhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Biliary tract neoplasms; Drug therapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CEDIRANIB; CETUXIMAB; CISPLATIN; DOXORUBICIN; ERLOTINIB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IMATINIB; LAPATINIB; MITOMYCIN; OXALIPLATIN; PANITUMUMAB; PLATINUM COMPLEX; SELUMETINIB; SORAFENIB; SUNITINIB; VANDETANIB; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BILE DUCT CARCINOMA; BILIARY TRACT CANCER; BILIARY TRACT DRAINAGE; BILIARY TRACT SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; DRUG EFFICACY; GALLBLADDER CANCER; HUMAN; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PANCREATICODUODENECTOMY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR VOLUME; VATER PAPILLA CARCINOMA; BILIARY TRACT NEOPLASMS; DISEASE COURSE; DISEASE FREE SURVIVAL; MORTALITY; PATHOLOGY; SALVAGE THERAPY; TIME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; SALVAGE THERAPY; TIME FACTORS; TREATMENT OUTCOME;

EID: 84883775443     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2013.28.5.515     Document Type: Review

References (72)

1. Randi G, Malvezzi M, Levi F, et al. Epidemiology of bili-ary tract cancers: an update. Ann Oncol 2009;20:146-159.
2. Center for Cancer Control and Information Services, National Cancer Center. Vital statistics [Internet]. Tokyo (JP): National Cancer Center, c2010 [cited 2013 Apr 18]. Available from: http://ganjoho.jp/professional/statistics/statistics.html.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
4. Jung KW, Park S, Won YJ, et al. Prediction of cancer in-cidence and mortality in Korea, 2012. Cancer Res Treat 2012;44:25-31.
5. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tu-mours. J Hepatol 2002;37:806-813.
6. Hezel AF, Zhu AX. Systemic therapy for biliary tract cancers. Oncologist 2008;13:415-423.
7. Miyakawa S, Ishihara S, Horiguchi A, Takada T, Mi-yazaki M, Nagakawa T. Biliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg 2009;16:1-7.
8. Sasaki T, Isayama H, Nakai Y, et al. Improvement of prognosis for unresectable biliary tract cancer. World J Gastroenterol 2013;19:72-77.
9. Tada M, Nakai Y, Sasaki T, et al. Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers. World J Clin Oncol 2011;2:158-163.
10. Glimelius B, Hoffman K, Sjoden PO, et al. Chemothera-py improves survival and quality of life in advanced pan-creatic and biliary cancer. Ann Oncol 1996;7:593-600.
11. Takada T, Nimura Y, Katoh H, et al. Prospective ran-domized trial of 5-f luorouracil, doxorubicin, and mi-tomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial. Hepatogas-troenterology 1998;45:2020-2026.
12. Sharma A, Dwary AD, Mohanti BK, et al. Best support-ive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol 2010;28:4581-4586.
13. Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007;96:896-902.
14. Yonemoto N, Furuse J, Okusaka T, et al. A multi-center retrospective analysis of survival benefits of chemo-therapy for unresectable biliary tract cancer. Jpn J Clin Oncol 2007;37:843-851.
15. Doval DC, Sekhon JS, Gupta SK, et al. A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Br J Cancer 2004;90:1516-1520.
16. Thongprasert S, Napapan S, Charoentum C, Moon-prakan S. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 2005;16:279-281.
17. Kim ST, Park JO, Lee J, et al. A Phase II study of gem-citabine and cisplatin in advanced biliary tract cancer. Cancer 2006;106:1339-1346.
18. Valle JW, Wasan H, Johnson P, et al. Gemcitabine alone or in combination with cisplatin in patients with ad-vanced or metastatic cholangiocarcinomas or other bil-iary tract tumours: a multicentre randomised phase II study: The UK ABC-01 Study. Br J Cancer 2009;101:621- 627.
19. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gem- citabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273-1281.
20. Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 2010;103:469-474.
21. Andre T, Tournigand C, Rosmorduc O, et al. Gemcitabi-ne combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 2004;15:1339-1343.
22. Harder J, Riecken B, Kummer O, et al. Outpatient che-motherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer 2006;95:848-852.
23. Andre T, Reyes-Vidal JM, Fartoux L, et al. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer 2008;99:862-867.
24. Kim HJ, Lee NS, Lee SC, et al. A phase II study of gem-citabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer. Cancer Chemother Pharmacol 2009;64:371-377.
25. Jang JS, Lim HY, Hwang IG, et al. Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial. Cancer Chemother Pharmacol 2010;65:641-647.
26. Cho JY, Paik YH, Chang YS, et al. Capecitabine com-bined with gemcitabine (CapGem) as first-line treat-ment in patients with advanced/metastatic biliary tract carcinoma. Cancer 2005;104:2753-2758.
27. Knox JJ, Hedley D, Oza A, et al. Combining gemcitabine and capecitabine in patients with advanced biliary can-cer: a phase II trial. J Clin Oncol 2005;23:2332-2338.
28. Riechelmann RP, Townsley CA, Chin SN, Pond GR, Knox JJ. Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer 2007;110:1307-1312.
29. Koeberle D, Saletti P, Borner M, et al. Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Re-search. J Clin Oncol 2008;26:3702-3708.
30. Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C. Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer 2004;91:1769-1774.
31. Furuse J, Okusaka T, Boku N, et al. S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Che-mother Pharmacol 2008;62:849-855.
32. Sasaki T, Isayama H, Yashima Y, et al. S-1 monotherapy in patients with advanced biliary tract cancer. Oncology 2009;77:71-74.
33. Sasaki T, Isayama H, Nakai Y, et al. Multicenter, phase II study of gemcitabine and S-1 combination chemo-therapy in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 2010;65:1101-1107.
34. Kanai M, Yoshimura K, Tsumura T, et al. A multi-insti-tution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 2011;67:1429-1434.
35. Sasaki T, Isayama H, Nakai Y, et al. A randomized phase II study of gemcitabine and S-1 combination therapy ver-sus gemcitabine monotherapy for advanced biliary tract cancer. Cancer Chemother Pharmacol 2013;71:973-979.
36. Morizane C, Okusaka T, Mizusawa J, et al. Randomized phase II trial of gemcitabine plus S-1 combination ther-apy versus S-1 in advanced biliary tract cancer: results of the Japan Clinical Oncology Group study (JCOG0805) [abstract]. J Clin Oncol 2012;30(4):abstr 255.
37. Kim YJ, Im SA, Kim HG, et al. A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer. Ann Oncol 2008;19:99-103.
38. Kang MJ, Lee JL, Kim TW, et al. Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cispla-tin in patients with advanced biliary tract adenocarci-noma. Acta Oncol 2012;51:860-866.
39. Kim TW, Chang HM, Kang HJ, et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol 2003;14:1115-1120.
40. Hong YS, Lee J, Lee SC, et al. Phase II study of capecit-abine and cisplatin in previously untreated advanced biliary tract cancer. Cancer Chemother Pharmacol 2007;60:321-328.
41. Sanz-Altamira PM, O'Reilly E, Stuart KE, et al. A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma. Ann Oncol 2001;12:501-504.
42. Alberts SR, Fishkin PA, Burgart LJ, et al. CPT-11 for bile-duct and gallbladder carcinoma: a phase II North Central Cancer Treatment Group (NCCTG) study. Int J Gastrointest Cancer 2002;32:107-114.
43. Jones DV Jr, Lozano R, Hoque A, Markowitz A, Patt YZ. Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. J Clin Oncol 1996;14:2306-2310.
44. Papakostas P, Kouroussis C, Androulakis N, et al. First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract: a multicentre phase II study. Eur J Cancer 2001;37:1833-1838.
45. Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 2006;24:3069-3074.
46. Ramanathan RK, Belani CP, Singh DA, et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharma-col 2009;64:777-783.
47. Bengala C, Bertolini F, Malavasi N, et al. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer 2010;102:68-72.
48. El-Khoueiry AB, Rankin CJ, Ben-Josef E, et al. SWOG 0514: a phase II study of sorafenib in patients with unre-sectable or metastatic gallbladder carcinoma and chol-angiocarcinoma. Invest New Drugs 2012;30:1646-1651.
49. Bekaii-Saab T, Phelps MA, Li X, et al. Multi-institution-al phase II study of selumetinib in patients with meta-static biliary cancers. J Clin Oncol 2011;29:2357-2363.
50. Lubner SJ, Mahoney MR, Kolesar JL, et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol 2010;28:3491-3497.
51. El-Khoueiry AB, Rankin C, Iqbal S, et al. SWOG 0941: a phase II study of sorafenib and erlotinib in patients (pts) with advanced gallbladder cancer or cholangiocarcino-ma [abstract]. J Clin Oncol 2012;30(15):abstr 4113.
52. Gruenberger B, Schueller J, Heubrandtner U, et al. Ce-tuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol 2010;11:1142-1148.
53. Malka D, Fartoux L, Rousseau V, et al. Gemcitabine and oxaliplatin (GEMOX) alone or in combination with ce-tuximab as first-line treatment for advanced biliary can-cer: final analysis of a randomized phase II trial (BINGO) [abstract]. J Clin Oncol 2012;30(15):abstr 4032.
54. Lee J, Park SH, Chang HM, et al. Gemcitabine and ox-aliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2012;13:181-188.
55. Zhu AX, Meyerhardt JA, Blaszkowsky LS, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-f luorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol 2010;11:48-54.
56. Walter T, Horgan AM, McNamara M, et al. Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study. Eur J Cancer 2013;49:329-335.
57. Lee MA, Woo IS, Kang JH, Hong YS, Lee KS. Gemcitabi-ne and cisplatin combination chemotherapy in intra-hepatic cholangiocarcinoma as second-line treatment: report of four cases. Jpn J Clin Oncol 2004;34:547-550.
58. Sasaki T, Isayama H, Nakai Y, et al. Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer. Invest New Drugs 2011;29:1488-1493.
59. Paule B, Herelle MO, Rage E, et al. Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with re-fractory advanced intrahepatic cholangiocarcinomas. Oncology 2007;72:105-110.
60. Oh SY, Jeong CY, Hong SC, et al. Phase II study of sec-ond line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness. Invest New Drugs 2011;29:1066-1072.
61. Suzuki E, Ikeda M, Okusaka T, et al. A multicenter phase II of S-1 in gemcitabine-refractory biliary tract cancer [abstract]. J Clin Oncol 2010;28(15):abstr 4145.
62. Sasaki T, Isayama H, Nakai Y, et al. Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gem-citabine. Invest New Drugs 2012;30:708-713.
63. Lim KH, Han SW, Oh DY, Im SA, Kim TY, Bang YJ. Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer. Oncology 2012;83:57-66.
64. Roth A, Schleyer E, Schoppmeyer K, et al. Imatinib me-sylate for palliative second-line treatment of advanced biliary tract cancer: a bicentric phase II study. Onkolo-gie 2011;34:469-470.
65. Yi JH, Thongprasert S, Lee J, et al. A phase II study of sunitinib as a second-line treatment in advanced bili-ary tract carcinoma: a multicentre, multinational study. Eur J Cancer 2012;48:196-201.
66. Katayose Y, Ohtsuka H, Kitamura Y, et al. An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer. Hepatogastroenterology 2012;59:691-695.
67. Kobayashi S, Ueno M, Ohkawa S, et al. A retrospective study of S-1 monotherapy as second-line treatment for patients with advanced biliary tract cancer. Jpn J Clin Oncol 2012;42:800-806.
68. Sasaki T, Isayama H, Nakai Y, et al. A retrospective study of gemcitabine and cisplatin combination therapy as second-line treatment for advanced biliary tract can-cer [abstract]. J Clin Oncol 2013;31(4):abstr 258.
69. Tempero MA, Arnoletti JP, Behrman SW, et al. Pancre-atic adenocarcinoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012;10:703-713.
70. Sasaki T, Isayama H, Ito Y, et al. Comparing the treat-ment outcomes between unresectable and recurrent cases receiving gemcitabine and S-1 combination che-motherapy in patients with advanced biliary tract can-cer: pooled analysis of two prospective studies [abstract]. J Clin Oncol 2012;30(4):abstr 331.
71. Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol 2010;28:3531-3540.
72. Sasaki T, Isayama H, Nakai Y, et al. Prognostic factors in patients with advanced biliary tract cancer receiv-ing chemotherapy. Cancer Chemother Pharmacol 2011;67:847-853.